EF Hutton Maintains Buy on Citius Pharma, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert maintains a Buy rating on Citius Pharma (NASDAQ:CTXR) with a $6 price target.
August 08, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert maintains a Buy rating on Citius Pharma with a $6 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $6 price target by a reputable analyst suggests positive sentiment and confidence in Citius Pharma's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100